Systematic Drug Discovery

In all of life that is relevant to disease, there are hundreds of thousands of proteins. Every drug compound binds in varying degrees to many different proteins, and can affect very many proteins in other ways, such as through changing their expression, or phosphorylation state. The huge variety of possible protein targets, and the large variety of patterns of possible effects on proteins create an enormous range of possible interactions between a drug molecule and any biological system. For this fundamental reason, the biological effects of a molecule's interactions with pathogenic, pathological and normal cells have been very difficult to predict.

e-Therapeutics has developed proprietary complex systems tools that can predict the biological effect of interference with one or many proteins in a cell. These very fast processes have been shown to predict biological effects accurately.

e-Therapeutics uses these capabilities to search for new drugs across several therapeutic areas; to search for new clinical uses for existing drugs; and to identify the probability of drug-drug interactions and toxicity.

Drug Discovery Programme

e-Therapeutics proprietary discovery program is focused on areas of high unmet medical need, for which there is good quality proteomics data. Discovery projects are underway in Alzheimer’s dementia, age-related macular degeneration, atherosclerosis, prostate cancer, and pain, in partnership with several companies.